News & Updates
Filter by Specialty:
Skin type factors in dupilumab efficacy in atopic dermatitis
The use of dupilumab in the treatment of atopic dermatitis appears to benefit patients who have dark skin types more than those who have light skin types, as shown in a study.
Skin type factors in dupilumab efficacy in atopic dermatitis
15 Oct 2022
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
First-line treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP1) receptor agonists improves outcomes in patients with type 2 diabetes (T2D), but to be cost-effective, the prices of these drugs must drop by at least 70 percent, suggests a study.
First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective
15 Oct 2022
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
In the long-term follow-up of the KEYNOTE-604 study, the combination regimen comprising pembrolizumab and etoposide/platinum (EP*) continued to demonstrate survival benefit as first-line therapy for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
14 Oct 2022
Prexasertib works in select patients with recurrent ovarian cancer
CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.